Fourth indication approved for gemcitabine


Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.